Controlled-release dosage forms of Azithromycin

Patent 6068859 Issued on May 30, 2000. Estimated Expiration Date:

November 4, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
Patent #: 4474768
Issued on: 10/02/1984
Inventor: Bright

11-Methyl-11-aza-4-0-cladinosyl-6-0-desosaminyl-15-ethyl-7,1 3,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one and derivatives thereof
Patent #: 4517359
Issued on: 05/14/1985
Inventor: Kobrehel , et al.

Drug dispenser comprising wall formed of semipermeable member and enteric member
Patent #: 4522625
Issued on: 06/11/1985
Inventor: Edgren

Generic zero order controlled drug delivery system
Patent #: 4792448
Issued on: 12/20/1988
Inventor: Ranade

Azithromycin and derivatives as antiprotozoal agents
Patent #: 4963531
Issued on: 10/16/1990
Inventor: Remington

Controlled porosity osmotic pump
Patent #: 4968507
Issued on: 11/06/1990
Inventor: Zentner, et al.

Controlled release formulation for poorly soluble basic drugs
Patent #: 5705190
Issued on: 01/06/1998
Inventor: Broad, et al.

High viscosity liquid controlled delivery system Patent #: 5747058
Issued on: 05/05/1998
Inventor: Tipton, et al.

Inventors

Application

No. 727634 filed on 11/04/1996

US Classes:

424/490, Coated (e.g., microcapsules)424/464, Tablets, lozenges, or pills424/465, With claimed perfecting feature in contents (e.g., excipient, lubricant, etc.)424/484, Matrices424/489Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)

Examiners

Primary: Page, Thurman K.
Assistant: Benston, William E. Jr.

Attorney, Agent or Firm

Richardson; Peter C., Benson; Gregg C., Jones; James T.

Foreign Patent References

0080341 EP. 07/13/1981
0109253 EP. 10/13/1987
0307128 EP 03/13/1989
0378404 EP. 07/13/1990
0582396 EP 02/13/1994
2066070 GB. 07/13/1981
2091097 GB. 07/13/1982
8902271 WO. 03/13/1989
9009168 WO. 08/13/1990
9101131 WO. 02/13/1991
9117744 WO 11/13/1991
9400112 WO. 01/13/1994
9509601 WO 04/13/1995

International Classes

A61K 009/16
A61K 009/50

Abstract

A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage form; and a method of treating a microbial infection, comprising administering azithromycin in such a controlled-release dosage form to a mammal, including a human patient, in need of such treatment.

Other References

Chem. Abstr., Yoshitomi, H., et al., V 119, No. 8, p. 496, abst. No. 79946v, "Evaluation of Enteric Coated Tablet Sensitive to Pancreatic Lipase I. In vitro Disintegration Test"
Martindale, The Extra Pharmacopoiea, 30th, The Pharm. Press, London, 1963, p. 1197
PDR, 48th, Med. L994, N.Y. p. 1789
The Merck Index, 11th, Merck & Co., N.Y., 1989, p. 146 Remington Pharmaceutical Science, 16th Merck Pub
Farmacia Practica de Remington, second Spanish edition, UTEHA, Mexico, 1965, pp. 471 and 525
Laegemiddelkataloget, Copenhagen 1992, p. 229, and p. 356 (including English Translation thereof)
Farmaceitisk Tidende, No. 35/36, 1988, p. 537-548 (including English Translation thereof)
Farmaceuten, No. 12, 1990, p. 402-405 (including English Translation thereof)
Hon-Leung Lee et al., "Drug Properties Influencing The Design of Sustained or Controlled Release Drug Delivery"
Chapters 88, 90, and 91 from Remington Pharmaceutical Science, 16th Merck Pub. Co., Pennsylvania (1980), pp. 1535, 1585, 1594
Scott Hopkins, The American Journal of Medicine, vol. 91, (Suppl 3A) Sep. 12, 1991, 3A-40S-3A-45S
J. R. Cardinal, Plenum Publishing Corp., 1984, Drug Release From Matrix Devices
Richard H. Drew, Pharmacotherapy, vol. 12, No. 3, 1992, pp. 162-17